Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18


Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.

Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R.

JAMA Oncol. 2016 Jul 1;2(7):890-8. doi: 10.1001/jamaoncol.2015.6275.


Proteomic Profiling of Serum-Derived Exosomes from Ethnically Diverse Prostate Cancer Patients.

Turay D, Khan S, Diaz Osterman CJ, Curtis MP, Khaira B, Neidigh JW, Mirshahidi S, Casiano CA, Wall NR.

Cancer Invest. 2016;34(1):1-11. doi: 10.3109/07357907.2015.1081921. Epub 2015 Nov 4.


The path to routine use of genomic biomarkers in the cancer clinic.

Boutros PC.

Genome Res. 2015 Oct;25(10):1508-13. doi: 10.1101/gr.191114.115. Review.


Prostate specific antigen: the past, present and future.

Gill H, Wu J.

Curr Urol. 2013 Feb;6(4):175-8. doi: 10.1159/000343535. Epub 2013 Feb 8. Review.


What do the screening trials really tell us and where do we go from here?

Etzioni RD, Thompson IM.

Urol Clin North Am. 2014 May;41(2):223-8. doi: 10.1016/j.ucl.2014.01.002. Epub 2014 Feb 19. Review.


Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

Wilt TJ, Scardino PT, Carlsson SV, Basch E.

J Natl Cancer Inst. 2014 Mar;106(3):dju010. doi: 10.1093/jnci/dju010. Epub 2014 Mar 4. No abstract available.


PSA mass screening: is there enough evidence?

Rocco B, Grasso A, Sosnowski R, Dell'orto PG, Albo G, Castle E, Coelho R, Patel V, Mottrie A.

Cent European J Urol. 2012;65(1):4-6. doi: 10.5173/ceju.2012.01.art1. Epub 2012 Mar 19. Review.


Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Jones DR.

Br J Pharmacol. 2014 Jun;171(12):2925-39. doi: 10.1111/bph.12601. Review.


Overdiagnosis and overtreatment of prostate cancer.

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.

Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9. Review.


Update of randomized trials for prostate cancer screening.

Vellekoop A, Loeb S.

Rev Urol. 2013;15(1):37-9. No abstract available.


Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Gulati R, Gore JL, Etzioni R.

Ann Intern Med. 2013 Feb 5;158(3):145-53. doi: 10.7326/0003-4819-158-3-201302050-00003.


Screening for pancreatic cancer: why, how, and who?

Poruk KE, Firpo MA, Adler DG, Mulvihill SJ.

Ann Surg. 2013 Jan;257(1):17-26. doi: 10.1097/SLA.0b013e31825ffbfb. Review.


Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.

Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, Hugosson J.

J Clin Oncol. 2012 Jul 20;30(21):2581-4. doi: 10.1200/JCO.2011.40.4327. Epub 2012 Jun 18. No abstract available.


Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes.

Kakehi Y.

Asian J Androl. 2012 May;14(3):361-4. doi: 10.1038/aja.2011.151. Epub 2012 Apr 16. Review.


Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

BJU Int. 2012 Feb;109(4):508-13; discussion 513-4. doi: 10.1111/j.1464-410X.2011.10900.x. Epub 2012 Feb 1.


Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.

Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.

J Clin Epidemiol. 2011 Dec;64(12):1412-7. doi: 10.1016/j.jclinepi.2011.06.011.


DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer.

Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J, Benson MC, Santella RM, Shen J.

DNA Cell Biol. 2012 Feb;31(2):187-92. doi: 10.1089/dna.2011.1311. Epub 2011 Aug 10.

Supplemental Content

Support Center